Subjects in the Mino-Lok arm get a daily dose of MLT with an apartment time of two to 4 hours for a total of seven doses. For the subjects in the group, the researcher determines the antibiotic used in the blockade, the dose, the apartment time and number of days of management based on institutional criteria or guidelines of the Infectious Diseases Society of America (IDSA).
About Biorasi, LLCBiorasi is a full-service, customer-focused contract study organization (CRO) that provides fast and flexible responses in global clinical trials to maximize speed to market for its sponsors. As a leader in neurology, nephrology, dermatology and the pressing disease market, Biorasi sets new criteria in speed, agility and quality in patient recruitment, decentralized trials and transparency of knowledge. Contact Biorasi in info@biorasi. com.
About Citius Pharmaceuticals, Inc. Citius is a late-stage biopharmaceutical company committed to advancing and commercializing world-class critical care products, with a focus on oncology, anti-infectives in complementary cancer care, proprietary prescription products and mobile stem cure products. The company has two late-stage product candidates, Mino-Lok®, an antibiotic lock solution for treating patients with catheter-related bloodstream infections (CRBSI), which is recently enrolling patients in a pivotal superiority trial and I/ONTAK (E7777), a new IL-2R immunocure for an initial indication in cutaneous T-mobile lymphoma (CTCL), which has completed enrollment in its pivotal phase 3 trial. Mino-Lok won Fast Track designation from the US Food and Drug Administration (FDA). I/ONTAK has earned orphan drug designation from the FDA for the treatment of CTCL and peripheral T-cell lymphoma (PTCL). Through its subsidiary, NoveCite, Inc. , Citius is introducing a new patented remedy based on a mesenchymal stem cell derived from induced pluripotent stem cells (iPSC) for acute respiratory conditions, with a short-term focus on respiratory distress (ARDS) related to COVID-19. For more information, make a stop at www. citiuspharma. com.
Safe Harbor This news release would possibly imply “forward-looking emails” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exposure Act of 1934. These emails are prepared on the basis of basis of our expectations and ideals. about long-term events have effects on Citius. You can identify these statements by the fact that they use words like “believe,” “anticipate,” “estimate,” “expect,” “plan,” “should,” and “possibly” and other words and terms of similar meaning. or the use of long-term dates. Forward-looking statements are based on management’s existing expectations and are subject to risks and uncertainties that may also have adverse effects on our business, effects of operations, monetary condition and inventory price. Factors that may also cause actual effects to differ materially from those currently expected include: our ability to initiate full clinical trials and the effects of such trials on applicants for our products; our ability to position our products in the marketplace if approved by the FDA; the estimated market position positions for our product applicants and their acceptance through any market position position; the ability of our product applicants to impact the quality of life of our target patient populations; the dangers related to the effects of the studies and progression activities, adding those of the existing and new assets of the pipeline; uncertainties similar to preclinical and clinical trials; our need for really extensive extra funds; the initial level of products in progression; our ability to attract, recruit and retain key personnel; our reliance on third party vendors; market position and other situations; similar dangers to our expansion strategy; patents and intellectual property; our ability to obtain, execute and maintain financing and strategic agreements and relationships; our ability to identify, acquire, close and integrate product applicants and corporations in an effective and timely manner; our ability to acquire cGMP supply on a commercial scale; government regulations; competition; and other hazards described in our SEC filings. These risks have been and may be more affected by Covid-19. Accordingly, such forward-looking statements are not promises of long-term performance, and you are cautioned not to place undue reliance on such forward-looking statements. The risks related to our business are described in detail in our filings with the Securities and Exhibitions Commission (“SEC”) found on the SEC’s online page at www. sec. gov, adding our annual report on Form 10-K for the tax year ending September 30. Array 2021, filed with the SEC on December 15, 2021 and updated through our upcoming SEC filings. These forward-looking emails speak only as of the date hereof, and we expressly disclaim any liability or obligation to publish any update or revision of any forward-looking email involved herein to reflect any reversal in our expectations or any reversal on the occasions , situations or cases in which it is based, except as required by law.
View content to download media: https://www. prnewswire. com/news-releases/citius-pharmaceuticals-to-accelerate-phase-3-mino-lok-trial-by-expanding-trial-sites-internationally-301541596Arrayhtml
SOURCECitius Pharmaceuticals, Inc.